stoxline Quote Chart Rank Option Currency Glossary
  
Recursion Pharmaceuticals, Inc. (RXRX)
10.53  2.03 (23.88%)    02-14 16:00
Open: 9.15
High: 10.755
Volume: 81,429,911
  
Pre. Close: 8.5
Low: 9.04
Market Cap: 4,041(M)
Technical analysis
2025-02-14 4:51:11 PM
Short term     
Mid term     
Targets 6-month :  12.55 1-year :  14.66
Resists First :  10.75 Second :  12.55
Pivot price 7.81
Supports First :  7.93 Second :  6.19
MAs MA(5) :  8.53 MA(20) :  7.67
MA(100) :  6.95 MA(250) :  7.99
MACD MACD :  0.4 Signal :  0.2
%K %D K(14,3) :  96.9 D(3) :  85
RSI RSI(14): 76
52-week High :  15.73 Low :  5.59
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RXRX ] has closed above the upper band by 33.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 79.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.76 - 10.8 10.8 - 10.85
Low: 8.95 - 8.99 8.99 - 9.03
Close: 10.45 - 10.53 10.53 - 10.6
Company Description

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Headline News

Sat, 15 Feb 2025
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.6% - What's Next? - MarketBeat

Sat, 15 Feb 2025
Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday? - Yahoo Canada Finance

Fri, 14 Feb 2025
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.6% Higher - What's Next? - MarketBeat

Fri, 14 Feb 2025
Why Recursion Pharmaceuticals Stock Is Soaring Today - Nasdaq

Fri, 14 Feb 2025
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Still a Buy? - MarketBeat

Fri, 14 Feb 2025
Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest (NASDAQ:RXRX) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 384 (M)
Shares Float 252 (M)
Held by Insiders 3.5 (%)
Held by Institutions 68.8 (%)
Shares Short 67,860 (K)
Shares Short P.Month 67,100 (K)
Stock Financials
EPS -1.54
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.83
Profit Margin 0 %
Operating Margin -377.2 %
Return on Assets (ttm) -36.5 %
Return on Equity (ttm) -78.5 %
Qtrly Rev. Growth 147.6 %
Gross Profit (p.s.) -0.69
Sales Per Share 0.16
EBITDA (p.s.) -0.95
Qtrly Earnings Growth 0 %
Operating Cash Flow -318 (M)
Levered Free Cash Flow -186 (M)
Stock Valuations
PE Ratio -6.84
PEG Ratio 0
Price to Book value 5.75
Price to Sales 61.99
Price to Cash Flow -12.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android